Bristol-Myers Squibb (BMY) Reports In-Line Q2 EPS, Updates FY EPS Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/10/2026

1. HUM
2. SPCX
3. ALHC
4. T
5. PEP
6. CVS
7. UNH
8. AXP
9. ZETA
10. DAL

Go back to Bristol-Myers Squibb (BMY) Reports In-Line Q2 EPS, Updates FY EPS Guidance

Bristol-Myers Squibb Reports Second Quarter Financial Results

July 27, 2017 6:59 AM EDT

Increases Second Quarter Revenues 6% to $5.1 Billion Posts Second Quarter GAAP EPS of $0.56 and Non-GAAP EPS of $0.74 Achieves Important Clinical and Regulatory Milestones in Immuno-Oncology Opdivo Approved in Europe for Advanced Form of Bladder Cancer and Squamous Cell Carcinoma of the Head and Neck Opdivo Application for Previously Treated Hepatocellular Carcinoma Granted Priority Review in the U.S. Yervoy Approved in the U.S. for Pediatric Patients with Metastatic Melanoma... More